Cargando…
Gene therapy for mucopolysaccharidoses: in vivo and ex vivo approaches
Mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders caused by a deficiency in lysosomal enzymes catalyzing the stepwise degradation of glycosaminoglycans (GAGs). The current therapeutic strategies of enzyme replacement therapy and allogeneic hematopoietic stem cell transplantation...
Autores principales: | Fraldi, Alessandro, Serafini, Marta, Sorrentino, Nicolina Cristina, Gentner, Bernhard, Aiuti, Alessandro, Bernardo, Maria Ester |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6238250/ https://www.ncbi.nlm.nih.gov/pubmed/30442177 http://dx.doi.org/10.1186/s13052-018-0565-y |
Ejemplares similares
-
Efficient Ex Vivo Engineering and Expansion of Highly Purified Human Hematopoietic Stem and Progenitor Cell Populations for Gene Therapy
por: Zonari, Erika, et al.
Publicado: (2017) -
A highly secreted sulphamidase engineered to cross the blood-brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA
por: Sorrentino, Nicolina Cristina, et al.
Publicado: (2013) -
The EHA Research Roadmap: Hematopoietic Stem Cell Gene Therapy
por: Naldini, Luigi, et al.
Publicado: (2022) -
Peripheral blood stem and progenitor cell collection in pediatric candidates for ex vivo gene therapy: a 10-year series
por: Canarutto, Daniele, et al.
Publicado: (2021) -
Gene therapy for ADA‐SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products
por: Aiuti, Alessandro, et al.
Publicado: (2017)